Final Trades: Amgen, Caterpillar, Honeywell and Freeport-McMoran
The Investment Committee give you their top stocks to watch for the second half.
Fiscal Year: January - December
Amgen Inc. (AMGN), listed on the NASDAQ, has a market capitalization of $. As of Jul 04, 2025, the stock is trading at $298.24 per share, offering investors a clear view of its current market value. Amgen Inc. is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of 27.25, investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. Amgen Inc. also offers a dividend yield of 3.21%, making it an attractive option for income-focused investors who seek regular dividends.
Our Discounted Cash Flow (DCF) analysis reveals that Amgen Inc. (AMGN) may be undervalued compared to its intrinsic worth. However, to see the exact DCF fair value, please Login or Upgrade for access.
The proprietary SS Score for Amgen Inc. is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for Amgen Inc., Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for Amgen Inc. is 14.69, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, Amgen Inc. (AMGN) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether Amgen Inc. (AMGN) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. Our analysis indicates that the stock may be undervalued compared to its intrinsic value. However, it is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of Amgen Inc. (AMGN) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of Amgen Inc.. To access the full SS Score, consider upgrading your subscription.
Amgen Inc. is a significant player in the industry sector, with a market capitalization of $ and a competitive P/E ratio of 27.25. Investors should compare these metrics with industry peers to gauge whether Amgen Inc. is outperforming or underperforming within its sector.
Amgen said on Monday its experimental cancer therapy, when combined with chemotherapy, met the main goal in a late-stage trial.
At an Interim Analysis, Bemarituzumab Plus Chemotherapy Significantly Improved Overall Survival in People With FGFR2b Overexpression Compared to Chemotherapy Alone THOUSAND OAKS, Calif. , June 30, 202...
Amgen Inc AMGN announced on Monday the full results from Part 1 of the Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133), a long-acting, peptide-antibody conjugate subcutaneously a...
Amgen stock (NASDAQ:AMGN) fell 6% on Monday, June 23, 2025, after mid-stage clinical trial results for its long-acting experimental obesity drug, MariTide, revealed a need for a low starting dose to m...
Amgen Inc. (NASDAQ:AMGN) Special Call (IR Call) Conference June 23, 2025 5:30 PM ET Company Participants Justin Claeys - Vice President of Investor Relations James Bradner - Executive Vice President ...
At the highest dosage of MariTide, 27% of patients stopped the drug due to a gastrointestinal adverse event.
People started on a low dose of Amgen's long-acting experimental obesity drug MariTide lost as much weight as those given high doses but with milder side effects, according to full results of a mid-st...
MariTide, the First Monthly or Less Frequently Dosed Obesity Treatment, Demonstrated Up to ~20% Average Weight Loss Without a Weight Loss Plateau, and Delivered Significant Cardiometabolic Improvement...
MariTide is the First Monthly or Less Frequently Dosed Peptide-Antibody Conjugate Being Investigated for the Treatment of Obesity and Type 2 Diabetes New Repatha® Data Provide Insight Into the Benefi...
Two Democratic lawmakers on Tuesday pressed five of the nation's largest pharmaceutical companies about their low tax bills and whether they support extending massive tax cuts for the industry in the ...
Despite the weak performance of Amgen's rare disease portfolio, it once again beat consensus non-GAAP EPS and revenue estimates. So, the main contributors to strengthening Amgen's balance sheet and im...
Amgen Inc. (NASDAQ:AMGN) Goldman Sachs 46th Annual Global Healthcare Conference Call June 10, 2025 9:20 PM ET Company Participants James E. Bradner - Executive Vice President of Research & Developmen...
Amgen faces major revenue risk from upcoming patent cliffs but has promising pipeline drugs like MariTide and olpasiran to offset losses. Recent financials show solid revenue growth and improved margi...
THOUSAND OAKS, Calif. , June 5, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the Goldman Sachs 46th Annual Global Healthcare Conference at 9:20 a.m.
Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, Medicare patients.
Breakthrough Second-Line Treatment Demonstrated Survival Advantage over Standard-of-Care Chemotherapy Late-Breaking Data Presented at ASCO 2025 and Simultaneously Published in The New England Journal...
Amgen's Imdelltra reduced the risk of death by 40% compared to chemotherapy for small cell lung cancer patients whose disease had worsened after an initial round of chemo, according to interim data fr...
THOUSAND OAKS, Calif. , May 30, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Jefferies Global Healthcare Conference at 9:20 a.m.
Amgen's Nplate, which treats low blood platelet counts caused by an autoimmune condition, was highly effective at preventing a similar common and serious complication of powerful chemotherapy cancer d...
Michael Yee, Jefferies senior biotech analyst, joins CNBC's 'Squawk on the Street' to discuss how AI could fuel drug discovery and development, the timeline for when pharmaceutical companies could see...
TROY, Mich. , May 27, 2025 /PRNewswire/ -- Stride Inc.'s recent report has investors wondering if the company's stock is overvalued.
Dividend stocks are facing many big risks. The high interest rates, trade war, and AI revolution could lead to many dividend cuts. I discuss what this all means for dividend investors.
Below estimates were sourced from SimplyWallSt and are intended for educational purposes only as a baseline for the analysis.
Year | FCF Estimate | % | # Analysts |
---|---|---|---|
2025 | 11.90B | 14.49% | Est @14.5% |
2026 | 13.41B | 12.66% | Analyst x6 |
2027 | 13.63B | 1.68% | Analyst x6 |
2028 | 13.77B | 1.01% | Analyst x4 |
2029 | 14.18B | 2.97% | Analyst x4 |
2030 | 14.41B | 1.60% | Est @1.6% |
2031 | 14.66B | 1.78% | Est @1.8% |
2032 | 14.94B | 1.91% | Est @1.9% |
2033 | 15.24B | 1.99% | Est @2.0% |
2034 | 15.53B | 1.93% | Est @1.9% |
Below are the FCF estimates with the discount factor and the calculated present value with the terminal value that led the results above.
Year | FCF | Discount Factor | PV of Future FCF |
---|---|---|---|
2023A | 7.36B | 1.00 | 7.36B |
2024A | 10.39B | 1.00 | 10.39B |
2025E | 11.90B | 1.08 | 11.03B |
2026E | 13.41B | 1.16 | 11.51B |
2027E | 13.63B | 1.26 | 10.85B |
2028E | 13.77B | 1.36 | 10.15B |
2029E | 14.18B | 1.46 | 9.69B |
2030E | 14.41B | 1.58 | 9.12B |
2031E | 14.66B | 1.70 | 8.60B |
2032E | 14.94B | 1.84 | 8.12B |
2033E | 15.24B | 1.99 | 7.68B |
2034E | 15.53B | 2.14 | 7.25B |
Terminal | 293.97B | 2.14 | 137.23B |
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.